"The Asia-Pacific region provides unprecedented opportunities for biotech companies to accelerate their clinical development program cost-effectively. The reforms at local government level and professionalization of the clinical trials service providers in the public and private sectors have created a new playing field."

Objective1: Discuss why Western biotech and VCs benefit from designing their clinical development programs with the Asia-Pacific rim in mind.

Objective2: Discuss the strategies for conducting early-phase and latephase clinical trials in patients of different ethnic origin.

Objective3: Discuss how Asia-Pacific hospital-based clinical research units have been able to jump-start their clinical trial management capabilities and their role in clinical development of therapeutics.